Fermer le menu

 

 

  • Presentations demonstrate the potential of AdoShell® for allogenic cell therapy in diabetes without immunosuppression, by delivering pancreatic human islets or iPSCs[1]
  • New preclinical data support AdoShell® Islets progression toward First-In-Human clinical trial submission in 2025
  • Data to be presented at the American Diabetes Association’s (ADA) 85th Scientific Sessions, the International Pancreas and Islet Transplant Association (IPITA) World Congress, the European Islets Study Group (EISG), and the International Society for Cell & Gene Therapy (ISCT) Annual Meeting

 

 

Read the press release

Plus d'infos